De novo metastatic castration sensitive prostate cancer: State of art and future perspectives

Claudia Mosillo, Roberto Iacovelli, Chiara Ciccarese, Emanuela Fantinel, Davide Bimbatti, Matteo Brunelli, Iolanda Bisogno, Stefania Kinspergher, Consuelo Buttigliero, Marcello Tucci, Orazio Caffo, Giampaolo Tortora

Research output: Contribution to journalReview article

Abstract

De novo metastatic castration sensitive prostate cancer (mCSPC) accounts for about 4% of all prostate tumors in Western Countries. This condition has a heterogeneous biological e clinical behavior, ranging from indolent to aggressive and rapidly fatal forms. Recently, the therapeutic landscape for mCSPC has been broadly enriched; indeed robust evidence supports the addiction of chemotherapy (docetaxel) or abiraterone acetate to androgen deprivation therapy (ADT), the latter considered for long the unique standard of care. However, the prognostic stratification and the definition of the ideal therapeutic approach for the subpopulation of de novo mCSPC – albeit largely represented in pivotal clinical trials enrolling mCSPC patients – have yet to be prospectively outlined. The aim of this review was to describe the current state of art about clinical presentation, prognostic classification, and different therapeutic options available for de novo mCSPC patients. Furthermore, we shed light on ongoing clinical trials and future perspectives for this disease setting.

Original languageEnglish
Pages (from-to)67-74
Number of pages8
JournalCancer Treatment Reviews
Volume70
DOIs
Publication statusPublished - Nov 1 2018

Keywords

  • Abiraterone
  • De novo metastatic castration sensitive prostate cancer
  • Docetaxel
  • mCSPC
  • Prognostic
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'De novo metastatic castration sensitive prostate cancer: State of art and future perspectives'. Together they form a unique fingerprint.

  • Cite this

    Mosillo, C., Iacovelli, R., Ciccarese, C., Fantinel, E., Bimbatti, D., Brunelli, M., Bisogno, I., Kinspergher, S., Buttigliero, C., Tucci, M., Caffo, O., & Tortora, G. (2018). De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. Cancer Treatment Reviews, 70, 67-74. https://doi.org/10.1016/j.ctrv.2018.08.005